Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer's Disease
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Sep 2019
Price : $35 *
At a glance
- Drugs Zagotenemab (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 30 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 19 Aug 2019 Planned End Date changed from 8 Oct 2021 to 22 Oct 2021.
- 19 Aug 2019 Planned primary completion date changed from 1 Jan 2021 to 23 Aug 2021.